Cycling was associated with reduced risk for both all-cause and cardiovascular (CV) mortality in people with diabetes, according to a study presented at EASD 2020 Meeting — suggesting that cycling could be encouraged as an activity to prevent deaths in this population who are known to have a higher mortality risk than the general public.
Fast eating increases post-prandial glucose (PPG) concentration and glycaemic excursion in young, healthy women without diabetes, an interventional study has shown, thus underscoring the role of eating speed in the development of type 2 diabetes (T2D) and obesity.
Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.
The dual orexin receptor antagonist suvorexant was effective in managing VMS*-associated insomnia among women in midlife, with further benefits for self-reported night-time, but not daytime, VMS, according to data presented at NAMS 2020.
Surufatinib, a novel small-molecule inhibitor that targets tumour angiogenesis and immune evasion, improves progression-free survival (PFS) in patients with progressive, advanced, well-differentiated pancreatic neuroendocrine tumours (pNETs), according to results of the SANET-p trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
SGLT-2 inhibitors may confer more cardiovascular (CV) protective benefits than GLP-1 RAs in patients with type 2 diabetes (T2D), according to a real-world study presented at the EASD 2020 virtual Congress.
Use of the sodium–glucose cotransporter 2 inhibitor empagliflozin in the treatment of type 2 diabetes (T2D) is effective even in patients with lower renal function and regardless of albuminuria status, with benefits including estimated glomerular filtration rate (eGFR) preservation, reduced body mass index, and lower risk of major adverse kidney events compared with other glucose-lowering drugs, as shown in a real-world study.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.